SecBot SecBot
SECBOTREPLAY Home › Report › VERA

VERA · Vera Therapeutics reported strong business progress with positive Phase…

Vera Therapeutics, Inc. · 8-K filed Feb 26, 2026 at 07:30 ET

At the news

MIXEDIMPACT 7/10

8-K filed Feb 26, 2026 at 07:30 ET

Vera Therapeutics reported strong business progress with positive Phase 3 data for atacicept in IgA nephropathy, FDA priority review granted with a PDUFA date of July 7, 2026, and a robust balance sheet from $800 million in financings. However, the company reported a significant net loss increase to $299.6 million in 2025 from $152.1 million in 2024, driven by higher R&D and G&A expenses.

  • Positive Phase 3 data from the ORIGIN 3 study of atacicept in IgA nephropathy presented at ASN Kidney Week and published in NEJM
  • FDA granted priority review to the Biologics License Application (BLA) for atacicept with a PDUFA date of July 7, 2026
  • Equity and debt financings in 2025 raised $800 million in gross proceeds, strengthening the balance sheet
  • Cash, cash equivalents, and marketable securities totaled $714.6 million as of December 31, 2025

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access